ET gradients in PCI and CMD
Research type
Research Study
Full title
Pilot translational clinical study to correlate levels of the potent vasoconstrictor peptide endothelin-1 with coronary microvascular dysfunction (CMD) in patients undergoing percutaneous coronary intervention (PCI)
IRAS ID
293242
Contact name
Stephen Hoole
Contact email
Sponsor organisation
University of Cambridge
Duration of Study in the UK
0 years, 3 months, 18 days
Research summary
Endothelin-1 (ET-1) is a molecule that potently constricts human coronary arteries. Our group are currently investigating the endothelin system as a novel drug target in coronary microvascular disease.
In this study, we plan to measure levels of ET-1 in blood samples taken from the aorta, coronary sinus and peripheral veins of patients with obstructive coronary artery disease, before and after percutaneous coronary intervention (PCI) using ELISA. The blood samples have been taken alongside invasive physiological measurements of coronary flow and anatomical atherosclerotic plaque characterisation using intra-coronary imaging as part of a previous study called the VIBE study.
We hypothesise the levels of ET-1 measured across the sampling sites will correlate with baseline invasive measures of microvascular dysfunction and atherosclerotic plaque structure.
The corresponding blood samples have been originally collected with ethical approval in a previous clinical trial sponsored by Papworth Hospital investigating biomarkers associated with myocardial injury during PCI.
Using these samples, we are additionally interested in identifying and quantifying other relevant peptides and proteins upregulated post PCI using Orbitrap Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS).
REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
20/WM/0330
Date of REC Opinion
17 Dec 2020
REC opinion
Favourable Opinion